NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...
Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for ...
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1 Protagonist eligible to receive $115 million milestone ...
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
Justin Flynn is an editor and writer from Ireland. He became a gamer at the age of eight when a mix-up at his local toy store landed him a copy of Kingdom Hearts. Since then, he has earned a Bachelor ...
Danny Guan is a writer with an avid interest in anime, manga, video games, and more. When he isn't writing for Game Rant, he's writing on his own personal website. The protagonist is always the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results